Amonafide: a potential role in treating acute myeloid leukemia

Bibliography

• Dohner H, Estey EH, Amadori S, Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010;115:453-74
   PubMed Web of Science ®Google Scholar
• Leith CP, Kopecky KJ, Godwin J, Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 1997;89:3323-9
   PubMed Web of Science ®Google Scholar
• Godwin JE, Kopecky KJ, Head DR, A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest oncology group study (9031). Blood 1998;20:3607-15
   Google Scholar
• Larson RA. Is secondary AML an independent poor prognostic factor in AML? Best Pract Res Clin Haematol 2007;20(1):29-37
   PubMed Web of Science ®Google Scholar
• Kayser S, Dohner K, Krauter J, , The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood 2011;117(7):2137-45
   PubMed Web of Science ®Google Scholar
• Anderson JE, Kopecky KJ, Willman CL, Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study. Blood 2002;100:3869-76
   PubMed Web of Science ®Google Scholar
• Appelbaum FR, Gundacker H, Head DR, Age and acute myeloid leukemia. Blood 2006;107:3481-5
   PubMed Web of Science ®Google Scholar
• Pirker R, Wallner J, Geissler K, MDR 1 gene expression and treatment outcome in acute myeloid leukemia. Cancer Inst 1991;83:708-12
   Google Scholar
• Willman CL. The prognostic significance of the expression and function of multidrug resistance transporter proteins in acute myeloid leukemia: studies of the Southwest Oncology Group Leukemia Research Program. Semin Hematol 1997;34(4 Suppl 5):25-33
   PubMed Web of Science ®Google Scholar
• Szakacs G, Paterson JK, Ludwig JA, Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006;5:219-34
   PubMed Web of Science ®Google Scholar
• Turk D, Szakacs G. Relevance of multidrug resistance in the age of targeted therapy. Curr Opin Drug Discov Devel 2009;12:246-52
   PubMed Web of Science ®Google Scholar
• Baer MR. Clinical significance of multidrug resistance in AML: current insights. Clin Adv Hematol Oncol 2005;3:910-12
   PubMedGoogle Scholar
• Baer MR, George SL, Dodge RK, Phase III study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood 2002;100:1224-32
   PubMed Web of Science ®Google Scholar
• Greenberg PL, Lee SJ, Advani R, Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high risk myelodysplastic syndrome: a Phase III trial (E2995). J Clin Oncol 2004;22:1078-86
   PubMed Web of Science ®Google Scholar
• Cripe LD, Li X, Litzow M, A randomized, placebo-controlled, double blind trial of the MDR modulator, zosuquidar, during conventional induction and post-remission therapy for Pts >60 years of age with newly diagnosed acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): ECOG 3999. Blood 2006;108:129a
   Web of Science ®Google Scholar
• Matsouka P, Pagoni M, Zikos P, Addition of cyclosporin-A to chemotherapy in secondary (post-MDS) AML in the elderly. A multicenter randomized trial of the Leukemia Working Group of the Hellenic Society of Hematology. Ann Hematol 2006; 85(4):250-617
   PubMed Web of Science ®Google Scholar
• Otake Y, Chau M, Ajami AM, Amonafide interferes with topoisomerase II binding to DNA and induces chromatin disorganization. AACR Meeting Abstracts 2008; Abs 647. Proc AACR 2008;49:152
   Google Scholar
• Brana MF, Castellano JM, Roldan CM, Synthesis and mode(s) of action of a new series of imide derivatives of 3-nitro-1,8 naphthalic acid. Cancer Chemother Pharmacol 1980;4:61-6
   PubMed Web of Science ®Google Scholar
• Otake Y, Chau M, Capizzi RL, Amonafide (AS1413) intercalates into DNA and is a unique inhibitor of DNA topoisomerase II. AACR Meeting Abstracts 2009; Abs 5858. Proc AACR
   Google Scholar
• Danks MK, Schmidt CA, Cirtain MC, Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukemic cells selected for resistance to VM-26. Biochemistry 1988;27:8861-9
   PubMed Web of Science ®Google Scholar
• Chen M, Beck WT. Teniposide-resistant CEM cells, which express mutant DNA topoisomerase II alpha, when treated with non-complex-stabilizing inhibitors of the enzyme, display no cross-resistance and reveal aberrant functions of the mutant enzyme. Cancer Res 1993;53:5946-53
   PubMed Web of Science ®Google Scholar
• Chau M, Christensen JL, Ajami AM, Capizzi RL. Amonafide, a topoisomerase II inhibitor, is unaffected by P-glycoprotein-mediated efflux. Leuk Res 2008;32:465-73
   PubMed Web of Science ®Google Scholar
• Burcu M, O'Loughlin KL, Ford LA, Baer MR. Amonafide l-malate is not a substrate for multidrug resistance proteins in secondary acute myeloid leukemia. Leukemia 2008;22:2110-15
   PubMed Web of Science ®Google Scholar
• Antisoma Research Ltd. Amonafide Investigator's Brochure. Version 8. 13 February2009
   Google Scholar
• Kreis W, Chan K, Budman DR, Clinical pharmacokinetics of amonafide (NSC 308847) in 62 patients. Cancer Invest 1996;14:320-7
   PubMed Web of Science ®Google Scholar
• Felder TB, McLean MA, Vestal ML, Pharmacokinetics and metabolism of the antitumor drug amonafide (NSC-308847) in humans. Drug Metab Dispos 1987;15:773-8
   PubMed Web of Science ®Google Scholar
• O'Brien S, Benvenuto JA, Estey E, Phase I clinical investigation of benzisoquinolinedione (amonafide) in adults with refractory or relapsed acute leukemia. Cancer Res 1991;51:935-8
   PubMed Web of Science ®Google Scholar
• Allen SL, Kolitz JE, Lundberg AS, Phase I trials of amonafide as monotherapy and in combination with cytarabine in patients with poor-risk acute myeloid leukemia. Leuk Res 2010;34:487-91
   PubMed Web of Science ®Google Scholar
• Erba HP. The combination of xanafide and cytarabine has unique activity in acute myeloid leukemia. Touch Briefings. Eur Oncol Dis 2007;2:30-1
   Google Scholar
• Allen SL, Erba HP, Rizzieri DA, Secondary acute myeloid leukemia (s AML) treated with amonafide (AS1413) + cytarabine: durable responses in poor-risk AML. ASH Annual Meeting Abstracts 2008; Abs 2968. Blood Nov 2008;112:2968
   Google Scholar
• Lundberg A, Chau M, Erba HP, Amonafide (AS1413) is unaffected by multidrug resistance and is associated with a high response rate in patients with secondary AML. EHA Annual Meeting Abstracts 2009: Abs 1058
   Google Scholar
• Erba HP, O'Donnell M, Allen SL, Amonafide (AS1413) in combination with cytarabine is equally effective in older and younger patients with secondary acute myeloid leukemia (sAML); final data from a Phase II study. ASH Annual Meeting Abstracts 2009: Abs 1047. Blood 2009;114:1047
   Google Scholar
• Downie BJ, Erba HP, Stone RM, Monosomal karyotype is predictive of poor response to therapy and worse overall survival in secondary acute myeloid leukemia (sAML); analysis of a multi-center phase II study of amonafide and cytarabine induction therapy. ASH Annual Meeting Abstracts: Abs 2076. Blood 2009;114:2076
   Google Scholar
• Breems DA, Van Putten WL, De Greef GE, Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol. 2008;26:4791-7
   PubMed Web of Science ®Google Scholar
• Lowenberg B, Ossenkopppele GJ, van Putten W, High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med 2009;361(13):1235-48
   PubMed Web of Science ®Google Scholar